Sumitomo Pharma America Inc.

3 trials 3 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

18 Countries active

4 Unique IMPs

N/A Results reported

Phase II/III

Phase I/II

Phase I (FiH)

Phase II/III: 1 Phase I/II: 1 Phase I (FiH): 1

Top indications

Myelofibrosis 1 Neurogenic bladder 1

Top IMPs

ENZOMENIB 1 MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE 1 NUVISERTIB 1 VIBEGRON 1

All trials

3 total

Open-label, long-term safety, efficacy, and pharmacokinetics study of vibegron in pediatric subjects 2 years to < 18 years of age with NDO a… Recruiting

2024-513995-16-00 Phase II/III 9 countries VIBEGRON
A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting

2022-502741-10-00 Phase I (FiH) 4 countries ENZOMENIB
Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting

2022-502597-16-00 Phase I/II 13 countries MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE; NUVISERTIB

Showing 1–3 of 3 trials

← All sponsors A–Z